Fate Therapeutics (FATE) Competitors $1.11 +0.06 (+5.71%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.11 0.00 (0.00%) As of 04/17/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. PRTC, SAGE, MNMD, KROS, CRMD, TYRA, PGEN, MAZE, ZVRA, and RVNCShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include PureTech Health (PRTC), Sage Therapeutics (SAGE), Mind Medicine (MindMed) (MNMD), Keros Therapeutics (KROS), CorMedix (CRMD), Tyra Biosciences (TYRA), Precigen (PGEN), Maze Therapeutics (MAZE), Zevra Therapeutics (ZVRA), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. PureTech Health Sage Therapeutics Mind Medicine (MindMed) Keros Therapeutics CorMedix Tyra Biosciences Precigen Maze Therapeutics Zevra Therapeutics Revance Therapeutics PureTech Health (NASDAQ:PRTC) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Do analysts rate PRTC or FATE? PureTech Health presently has a consensus target price of $45.00, indicating a potential upside of 165.80%. Fate Therapeutics has a consensus target price of $5.43, indicating a potential upside of 389.06%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than PureTech Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.22 Which has more risk & volatility, PRTC or FATE? PureTech Health has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.41, meaning that its share price is 141% more volatile than the S&P 500. Is PRTC or FATE more profitable? PureTech Health has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,325.43%. PureTech Health's return on equity of 0.00% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PureTech HealthN/A N/A N/A Fate Therapeutics -1,325.43%-45.88%-33.95% Do insiders and institutionals have more ownership in PRTC or FATE? 0.0% of PureTech Health shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 5.3% of PureTech Health shares are held by insiders. Comparatively, 5.0% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer PRTC or FATE? Fate Therapeutics received 471 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 67.51% of users gave Fate Therapeutics an outperform vote while only 45.00% of users gave PureTech Health an outperform vote. CompanyUnderperformOutperformPureTech HealthOutperform Votes945.00% Underperform Votes1155.00% Fate TherapeuticsOutperform Votes48067.51% Underperform Votes23132.49% Which has preferable valuation and earnings, PRTC or FATE? PureTech Health has higher earnings, but lower revenue than Fate Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPureTech Health$3.33M122.11-$65.70MN/AN/AFate Therapeutics$13.63M9.33-$160.93M-$1.64-0.68 Does the media refer more to PRTC or FATE? In the previous week, Fate Therapeutics had 2 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for PureTech Health. PureTech Health's average media sentiment score of 0.95 beat Fate Therapeutics' score of 0.27 indicating that PureTech Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPureTech Health beats Fate Therapeutics on 9 of the 17 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$127.21M$2.84B$5.30B$7.34BDividend YieldN/A1.86%5.12%4.30%P/E Ratio-0.6730.4821.8017.77Price / Sales9.33441.91379.9097.68Price / CashN/A168.6838.2634.64Price / Book0.303.466.443.98Net Income-$160.93M-$72.06M$3.21B$247.52M7 Day Performance4.72%2.56%2.84%1.82%1 Month Performance20.59%-15.70%-8.65%-6.98%1 Year Performance-77.98%-26.10%11.38%1.49% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics3.495 of 5 stars$1.11+5.7%$5.43+389.1%-78.9%$127.21M$13.63M-0.67550News CoveragePRTCPureTech Health3.0106 of 5 stars$17.30flat$45.00+160.1%-37.1%$415.53M$3.33M0.00100Upcoming EarningsShort Interest ↓High Trading VolumeSAGESage Therapeutics3.8763 of 5 stars$6.66-2.9%$8.81+32.3%-40.9%$409.46M$41.24M-1.01690Analyst RevisionMNMDMind Medicine (MindMed)2.1178 of 5 stars$5.43flat$25.11+362.5%-39.5%$409.25MN/A-2.4040Analyst RevisionKROSKeros Therapeutics3.4694 of 5 stars$9.98flat$42.33+324.2%-76.3%$404.81M$3.55M-1.92100High Trading VolumeCRMDCorMedix2.8564 of 5 stars$6.07+3.6%$15.14+149.5%+41.0%$395.66M$43.47M-7.4930Gap DownTYRATyra Biosciences2.1865 of 5 stars$7.38-4.7%$30.83+317.8%-38.3%$391.80MN/A-4.5820News CoveragePositive NewsPGENPrecigen3.1762 of 5 stars$1.33+7.3%$7.00+426.3%+6.1%$391.08M$3.93M-2.42190Gap DownMAZEMaze TherapeuticsN/A$8.92-1.7%$25.67+187.7%N/A$390.66M$167.50M0.00121ZVRAZevra Therapeutics2.5467 of 5 stars$7.05+0.1%$22.29+216.1%+54.1%$381.52M$23.61M-3.5820News CoverageGap DownRVNCRevance Therapeutics2.0848 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500 Related Companies and Tools Related Companies PureTech Health Alternatives Sage Therapeutics Alternatives Mind Medicine (MindMed) Alternatives Keros Therapeutics Alternatives CorMedix Alternatives Tyra Biosciences Alternatives Precigen Alternatives Maze Therapeutics Alternatives Zevra Therapeutics Alternatives Revance Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
